May 26, 2016
May 26, 2016 —
More than 8,000 students of the University of California San Diego will graduate during the campus’s commencement weekend June 11 and 12, beginning with the All Campus Commencement featuring keynote speaker Muhammad Yunus, a Nobel Peace Prize recipient and founder of the global microfinance movement. The event, at 10 a.m. on Saturday, June 11, will mark the first time in 16 years that UC San Diego will convene all of its graduating undergraduate and graduate students for a campus-wide commencement ceremony.
May 23, 2016
May 23, 2016 —
In a paper published in the current Journal of Alzheimer’s Disease, researchers at University of California San Diego School of Medicine and Veterans Affairs San Diego Healthcare System say existing screening tools for mild cognitive impairment (MCI) result in a false-negative error rate of more than 7 percent. These persons are misclassified as not having MCI based on standard screening instruments but actually do have MCI when more extensive testing is conducted.
May 20, 2016
May 20, 2016 —
All scientific achievement begins with an idea. Yesterday, three researchers at University of California San Diego School of Medicine were awarded funding by the Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine (CIRM) to pursue budding ideas that might eventually impact the field of human stem cell research.
May 19, 2016
May 19, 2016 —
Immunology – and the idea that many diseases can best be addressed by boosting the body’s own immune response – is one of the hottest areas in medical research and clinical treatment. University of California San Diego School of Medicine and Chiba University School of Medicine in Japan have announced a new collaborative research center to investigate the most promising aspects of immunology, especially the area of mucosal immunology, and to speed development of clinical applications.
May 19, 2016
May 19, 2016 —
Researchers at University of California San Diego School of Medicine and Sanford Burnham Prebys Medical Discovery Institute have discovered that high levels of the protein p62 in human liver samples are strongly associated with cancer recurrence and reduced patient survival. In mice, they also found that p62 is required for liver cancer to form.
May 19, 2016
May 19, 2016 —
IBM's World Community Grid and scientists from Brazil, the Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego, and Rutgers New Jersey Medical School have launched OpenZika, a project to find drug candidates to treat Zika.
May 17, 2016
May 17, 2016 —
While investigating a potential therapeutic target for the ERK1 and 2 pathway, a widely expressed signaling molecule known to drive cancer growth in one third of patients with colorectal cancer, University of California San Diego School of Medicine researchers found that an alternative pathway immediately emerges when ERK1/2 is halted, thus allowing tumor cell proliferation to continue.
May 16, 2016
May 16, 2016 —
Injections of the soil bacterium Mycobacterium vaccae promote stress resilience and improve coping behaviors in mice, according to a new study led by researchers at University of California San Diego School of Medicine and University of Colorado Boulder. The researchers also found that
May 13, 2016
May 13, 2016 —
On May 13, the White House Office of Science and Technology Policy (OSTP) announced a new National Microbiome Initiative, a coordinated effort to better understand microbiomes and to develop tools to protect and restore healthy microbiome function. OSTP is launching the initiative with a combined federal agency investment of more than $121 million. The University of California San Diego is a key participant in this effort, investing $12 million in its own microbiome research efforts.
May 12, 2016
May 12, 2016 —
A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia.
